Monthly MS injection aims to halt disability progression
NCT ID NCT03362294
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a long-acting form of glatiramer acetate (GA Depot) given as a monthly shot to people with primary progressive multiple sclerosis (PPMS). The goal was to see if it could safely slow down worsening disability. The trial was stopped early, but it involved 30 adults aged 18-65 with PPMS who received either 25 mg or 40 mg of the drug every four weeks for nearly three years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mapi Pharma Research site 01
Tel Aviv, Israel
-
Mapi Pharma Research site 06
Rehovot, Israel
-
Mapi Pharma Research site 07
Jerusalem, Israel
-
Mapi Pharma Research site 08
Petah Tikva, Israel
-
Mapi Pharma Research site 09
Haifa, Israel
-
Mapi Pharma Research site 20
Chisinau, Moldova
-
Mapi Pharma Research site 22
Chisinau, Moldova
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blood pressure pill slow MS disability?
- Could a simple injection replace an IV for MS treatment?
- Could a common supplement fight fatigue in progressive MS?
- Tears may replace spinal taps for MS diagnosis
- Nurse-Led video calls aim to empower MS patients
- Cheaper MS drug could match pricey standard in major trial